Discovery Research From The Editor

31. Talent Logistics Turns Biotech Winter To Hiring Spring 3/3/2025

    After our "Biotech Winter" – a period starting circa 2021 with tens of thousands of layoffs and stagnating investment — is it springtime for biotech? Chris Frew, Founder/CEO of BioBuzz Networks, says yes. “We have demonstrably entered a turning point in biotech hiring.”

32. CDMOs Bet Big On Asia Expansion. Can Trump Reverse The Tide? 2/20/2025

    Facility investments by CDMOs continue to be magnetized to Asia. Recent examples abound. Chief Editor Louis Garguilo details some of those, and discusses whether, for example, a President Trump-intensified focus on increasing manufacturing in the U.S. can change this. Will your outsourcing in 2025 change direction? The answer may surprise you.

33. Stop Hiring Now! Stay Virtual 2/17/2025

    Robert Discordia, Co-Founder, President and CEO, EQUULUS Therapeutics, knows that to advance early-stage development assets most economically, biotechs should (a) stay within their virtual model, and (b) base that outsourcing strategy on initial business objectives. Here are his dos and don'ts.

34. Training Specifically For Tech Transfer Skills Does Exist 2/3/2025

    Professionals in our development and manufacturing outsourcing ecosystem are worried about inadequate training – in-house at their biotechs, and at their CDMOs. A main concern is a lack of sufficiently trained personnel to perform the various technology transfers to keep our industry running efficiently.

35. An Outsourcing Vibe At JP Morgan 25 1/28/2025

    The JP Morgan Healthcare conference has never been a venue for directed discussion on outsourcing. That’s not to say such discussions aren’t held. This year, Kurt Nielsen co-hosted an evening devoted to the topic. Nielsen, a veteran outsourcing-industry executive, shares his initial thoughts on the vibe this year.

36. The Intelligent CDMO: A Vision With Agentic AI 1/20/2025

    Agentic AI is the next artificial-intelligence iteration for the biopharma industry. It propels prediction to autonomous decision-making. It can usher in transformative efficiencies to CDMOs. If you've day-dreamed of more effective external-support, this may be a ticket to that destination.

37. Autonomous Decision-Making: Are We Ready For Agentic AI 1/15/2025

    The biopharma industry has generative artificial intelligence (AI) in its employ. After a long wait, we’ve adopted it rather suddenly. Just in time for a new kid in town. Next to ride in is Agentic AI. It will more robustly revolutionize our drug development and manufacturing. A preview of what's to come.

38. It's Partly Personal (Medicine): In 10 Years Outsourcing At $315 Billion 1/13/2025

    You’ve got to give Towards Healthcare credit. They've the fortitude to publish a 10-year projection of how much development and manufacturing outsourcing will add up to globally. Interestingly, personalized medicine may play an outsized role in that growth. Chief Editor Louis Garguilo takes a deeper dive into the Pharmaceutical CDMO Market Companies, Advantages and Segmental Analysis.

39. 2024 Made Us Nervous. Will 2025 Be A Happier New Year? 1/6/2025

    Chief Editor Louis Garguilo doesn't recall a time of more collective concern over development and manufacturing outsourcing than exhibited during last year's news of Novo Holdings’ purchase of Catalent, and the sale of certain Catalent facilities to Novo Nordisk. That angst was aggravated by the simultaneous drama known as the BIOSECURE Act. Will we have a calmer 2025?

40. 2025: Navigating Partnerships Amid Political And Economic Shifts 1/2/2025

    Brace for a potentially turbulent 2025. That’s the collective message members of the Outsourced Pharma Editorial Advisory Board provided Chief Editor Louis Garguilo for his first editorial of 2025. They reveal a landscape where geopolitical tensions, regulatory evolutions, and emerging technologies will affect how you develop and manufacture drugs.